Joseph Catanzaro
Stock Analyst at Mizuho
(4.03)
# 741
Out of 5,170 analysts
107
Total ratings
46.07%
Success rate
13.99%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Outperform | $16 → $19 | $15.26 | +24.51% | 1 | Mar 13, 2026 | |
| TNGX Tango Therapeutics | Maintains: Outperform | $19 → $20 | $19.32 | +3.52% | 3 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Outperform | $26 | $10.98 | +136.79% | 1 | Mar 2, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $14.92 | +134.58% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $8.82 | -20.63% | 6 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6.5 → $10 | $4.78 | +109.21% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $99.29 | +44.02% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $14.22 | +174.26% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $8.38 | +508.59% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $18.79 | -4.20% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $53 | $42.31 | +25.27% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $120 | $79.57 | +50.81% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $30.03 | +59.84% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $105 | $68.50 | +53.28% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $3.87 | +55.04% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $12.20 | +268.85% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $141.11 | -22.05% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $41.26 | -7.90% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $11.12 | +34.89% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $63.27 | -16.23% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.82 | +449.45% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.09 | +1,643.12% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $9.69 | +96.08% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.15 | +597.67% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $11.49 | +213.32% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $21.39 | +87.00% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $8.27 | +81.38% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.99 | +50.50% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.70 | +1,664.71% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.17 | +1,609.40% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.06 | -42.81% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $22.33 | -10.43% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.87 | -47.74% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $30.55 | +554.66% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $14.22 | +146.13% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.32 | +4,445.45% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.35 | +665.96% | 3 | Apr 7, 2020 |
Erasca
Mar 13, 2026
Maintains: Outperform
Price Target: $16 → $19
Current: $15.26
Upside: +24.51%
Tango Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $19 → $20
Current: $19.32
Upside: +3.52%
Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $10.98
Upside: +136.79%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $14.92
Upside: +134.58%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $8.82
Upside: -20.63%
CytomX Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $6.5 → $10
Current: $4.78
Upside: +109.21%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $99.29
Upside: +44.02%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $14.22
Upside: +174.26%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $8.38
Upside: +508.59%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $18.79
Upside: -4.20%
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $42.31
Upside: +25.27%
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $79.57
Upside: +50.81%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $30.03
Upside: +59.84%
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $68.50
Upside: +53.28%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.87
Upside: +55.04%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $12.20
Upside: +268.85%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $141.11
Upside: -22.05%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $41.26
Upside: -7.90%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $11.12
Upside: +34.89%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $63.27
Upside: -16.23%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.82
Upside: +449.45%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.09
Upside: +1,643.12%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $9.69
Upside: +96.08%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.15
Upside: +597.67%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $11.49
Upside: +213.32%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $21.39
Upside: +87.00%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $8.27
Upside: +81.38%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.99
Upside: +50.50%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.70
Upside: +1,664.71%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.17
Upside: +1,609.40%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.06
Upside: -42.81%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $22.33
Upside: -10.43%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.87
Upside: -47.74%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $30.55
Upside: +554.66%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $14.22
Upside: +146.13%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.32
Upside: +4,445.45%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.35
Upside: +665.96%